

About ART™ System

Forward Looking Statement

This presentation contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward-looking statements when it discusses the ART's potential benefits, the ART business model, its vision, advantages of the ART and the advantages of the ART's components. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Registration Statement on Form F-1 filed with the SEC, which is available on the SEC's website, www.sec.gov.

About Inspira™



- Minimize the need for mechanical ventilation
- An Israeli medical device company, incorporated in 2018
- Mission- to create a paradigm shift in respiratory care
- Multiple patent applications supporting both innovation and intended use
- Supporting initial pre-clinical evidence (In-vivo)
- Management team with track record in medical & public companies

The ART™ System*

- A novel early-stage extracorporeal approach
- Potentially minimize the need for invasive mechanical ventilation (MV)
- Designed to be applied in awake & spontaneously breathing patients



Business

- The oxygenation and carbon dioxide removal respiratory system substituting MV, designed to be used both in and beyond the ICU
- US- a primary target market
- Recurring revenue business model based on sale of disposables

* ART system - An extracorporeal respiratory support system composed of an oxygenator, a pump and pump head a plug-and-play cartridge, sensors, and a control unit.
The Company's product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA) or the CE or other required regulatory agencies.

A blurred, high-angle shot of a large crowd of people walking in a public space, possibly a transit station or a busy street. The image is overlaid with a semi-transparent blue and red gradient. The text is positioned on the left side of the image.

Vision

Redefining Artificial
Respiration
to impact millions of lives

A New Approach to Minimize the Need for Mechanical Ventilation



Mechanical Ventilation

IV sedation

Intubation

Artificial Respiration

Ventilator Associated Complications

Weaning

Discharge



Inspira's ART™ System*

Awake Patient

Cannula Insertion

Hemo-dynamic extracorporeal treatment

Discharge

* These photos are for illustration purposes only. The Company's product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA) or the CE or other required regulatory agencies.

About ART™

Extracorporeal approach

A first-in-class system specifically designed to provide continuous low-flow venous-venous extracorporeal respiratory support

Cannula is designed to draw blood at a rate of 1-1.5L per minute¹

Rapid oxygenation improvement & CO2 removal

O2 saturation level is raised in minutes²

Low flow utilization

Designed to reduce clotting and hemolysis

Compact & portable

Designed for ICUs, general medical wards & ambulatory settings



1. In adult patients

2. In August 2020, animal studies were performed in swine model at LAHAV CRO in Israel. 25 hypoxemic events were induced, in order to test ARTs' oxygenation and carbon dioxide removal capabilities. In 20 out of the 25 hypoxemic events induced, ART treatment was provided with a blood flow rate of 1 liter per minute.

The Cannula

Small diameter

Dual lumen cannula, 16-21Fr in diameter*

One entry point, reduces risks of bleeding and infections

Simple placement

Cannula is inserted to the jugular vein and positioned in the superior vena cava, above the right atrium

Reduces the need for medical personnel who are specialized in extracorporeal respiratory systems

Cannula designed to be inserted by any ICU practitioner**

Reduces the need for surgical team

Minimize the need for radiography

Designed short length cannula minimize the need for positioning



* The diameter of the cannula depends on the flow volume required to perform the treatment. As the volume of flow decreases, the cannula diameter is reduced accordingly.

** During the market penetration phase, the Company anticipates the ART will be used in ICUs

Designed to Allow Utilization In Hospitals Without Prior ECMO Experience

A novel design minimizes the need for a perfusionist*


A novel “plug and play” disposable cartridge

- Minimize the need for a perfusionist to put together disposable parts
- Any nurse can insert cartridge and operate the system

A Novel auto-priming system

- Priming is done automatically
- Designed to prevent human errors
- Minimize the need for a perfusionist to assemble disposable parts
- Any nurse can insert cartridge and operate the system

* Perfusionist - operates a heart-lung machine (extracorporeal respiratory system), which is an artificial blood pump, which propels oxygenated blood to the patient's tissues (Britannica.com)



ART's Proprietary Hemo-Protective Flow Technology Features

Blood protection

ART's designed features

Hemolysis reduction

Thrombosis reduction

A unique (Low) flow-velocity ratio maintained throughout blood passage in disposable set

✓

✓

A low-volume oxygenator

✓

Pump head design for low flow

✓

✓

Short dual lumen cannula design

✓

Entire disposable set is coated with anticoagulants


✓

Hemolysis –breakdown or destruction of red blood cells so that the contained oxygen carrying pigment hemoglobin is freed into the surrounding medium²

Thrombosis – formation of a blood clot in the heart or in a blood vessel³

1. In August 2020, animal studies were performed in swine model at LAHAV CRO in Israel.

2-3. www.Britannica.com



1-1.5 liters of blood are being enriched with oxygen, rebalance patient's oxygen saturation levels in minutes¹


60+ Seconds to Relief*

"I was able to witness the insertion and positioning of the ART cannula, which was completed without the need for imaging. The ART system's capability to elevate oxygen saturation levels in a stable fashion, and all within a minute, is outstanding".


Prof. Eli Gabbay, Professor of Respiratory Medicine (Australia)

Pre-Clinical Results¹

SaO2 **Before** ARTTM notiativa



SaO2 **With** ARTTM activation



1. In August 2020, animal studies were performed in swine model at LAHAV CRO in Israel.



THANK YOU